Patents by Inventor Ruoping ZHANG

Ruoping ZHANG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11319346
    Abstract: The invention provides processes of purifying a peptide including a GCC agonist sequence selected from the group consisting of SEQ ID NOs: 1-251 described herein. The processes include a solvent exchange step before a freeze-drying (lyophilization) step.
    Type: Grant
    Filed: September 17, 2021
    Date of Patent: May 3, 2022
    Assignee: Bausch Health Ireland Limited
    Inventors: Kunwar Shailubhai, Stephen Comiskey, Rong Feng, Juncai Bai, Ruoping Zhang, Jun Jia, Junfeng Zhou, Qiao Zhao, Guoqing Zhang
  • Publication number: 20220119449
    Abstract: The invention provides processes of purifying a peptide including a GCC agonist sequence selected from the group consisting of SEQ ID NOs: 1-251 described herein. The processes include a solvent exchange step before a freeze-drying (lyophilization) step.
    Type: Application
    Filed: August 9, 2021
    Publication date: April 21, 2022
    Inventors: Kunwar Shailubhai, Stephen Comiskey, Rong Feng, Juncai Bai, Ruoping Zhang, Jun Jia, Junfeng Zhou, Qiao Zhao, Guoqing Zhang
  • Patent number: 11295657
    Abstract: The present disclosure discloses a method and system for switched display of a grayscale of a multi-line scan light-emitting diode (LED), and relates to the field of LED display technology. In view of the problems in the prior art that a multi-line scan constant-current source chip has an insufficient refresh rate, a low grayscale level, and a poor low-grayscale effect, the present disclosure provides a method during the display of relatively high grayscales, a display cycle is scrambled. During the display of relatively low grayscales, the grayscales are combined. In the present disclosure, a relatively high refresh rate and a grayscale level can still be ensured in a case of a relatively large quantity of line scans. In addition, in the case of low-grayscale display, the problems such as low-grayscale speckles, slightly dark low-grayscale, and relatively poor low-grayscale linearity are resolved, thereby improving a picture display effect.
    Type: Grant
    Filed: March 31, 2020
    Date of Patent: April 5, 2022
    Assignee: PURESEMI CO., LTD.
    Inventors: Ruoping Zhang, Xiao Song, Zhaoyu Jiang, Shuzhuan He
  • Publication number: 20210407367
    Abstract: The present disclosure discloses a method and system for switched display of a grayscale of a multi-line scan light-emitting diode (LED), and relates to the field of LED display technology. In view of the problems in the prior art that a multi-line scan constant-current source chip has an insufficient refresh rate, a low grayscale level, and a poor low-grayscale effect, the present disclosure provides a method during the display of relatively high grayscales, a display cycle is scrambled. During the display of relatively low grayscales, the grayscales are combined. In the present disclosure, a relatively high refresh rate and a grayscale level can still be ensured in a case of a relatively large quantity of line scans. In addition, in the case of low-grayscale display, the problems such as low-grayscale speckles, slightly dark low-grayscale, and relatively poor low-grayscale linearity are resolved, thereby improving a picture display effect.
    Type: Application
    Filed: March 31, 2020
    Publication date: December 30, 2021
    Inventors: Ruoping ZHANG, Xiao SONG, Zhaoyu JIANG, Shuzhuan HE
  • Publication number: 20210403508
    Abstract: The invention provides processes of purifying a peptide including a GCC agonist sequence selected from the group consisting of SEQ ID NOs: 1-251 described herein. The processes include a solvent exchange step before a freeze-drying (lyophilization) step.
    Type: Application
    Filed: September 17, 2021
    Publication date: December 30, 2021
    Inventors: Kunwar Shailubhai, Stephen Comiskey, Rong Feng, Juncai Bai, Ruoping Zhang, Jun Jia, Junfeng Zhou, Qiao Zhao, Guoqing Zhang
  • Patent number: 11142549
    Abstract: The invention provides processes of purifying a peptide including a GCC agonist sequence selected from the group consisting of SEQ ID NOs: 1-251 described herein. The processes include a solvent exchange step before a freeze-drying (lyophilization) step.
    Type: Grant
    Filed: July 6, 2020
    Date of Patent: October 12, 2021
    Assignee: Bausch Health Ireland Limited
    Inventors: Kunwar Shailubhai, Stephen Comiskey, Rong Feng, Juncai Bai, Ruoping Zhang, Jun Jia, Junfeng Zhou, Qiao Zhao, Guoqing Zhang
  • Publication number: 20200399315
    Abstract: The invention provides processes of purifying a peptide including a GCC agonist sequence selected from the group consisting of SEQ ID NOs: 1-251 described herein. The processes include a solvent exchange step before a freeze-drying (lyophilization) step.
    Type: Application
    Filed: July 6, 2020
    Publication date: December 24, 2020
    Inventors: Kunwar Shailubhai, Stephen Comiskey, Rong Feng, Juncai Bai, Ruoping Zhang, Jun Jia, Junfeng Zhou, Qiao Zhao, Guoqing Zhang
  • Patent number: 10745441
    Abstract: The invention provides processes of purifying a peptide including a GCC agonist sequence selected from the group consisting of SEQ ID NOs: 1-251 described herein. The processes include a solvent exchange step before a freeze-drying (lyophilization) step.
    Type: Grant
    Filed: June 5, 2018
    Date of Patent: August 18, 2020
    Assignee: Bausch Health Ireland Limited
    Inventors: Kunwar Shailubhai, Stephen Comiskey, Rong Feng, Juncai Bai, Ruoping Zhang, Jun Jia, Junfeng Zhou, Qiao Zhao, Guoqing Zhang
  • Publication number: 20200040038
    Abstract: The invention provides processes of preparing a peptide including a GCC agonist sequence selected from the group consisting of SEQ ID NOs: 1-249 described herein.
    Type: Application
    Filed: August 21, 2019
    Publication date: February 6, 2020
    Inventors: Juncai Bai, Ruoping Zhang, Jun Jian, Junfeng Zhou, Qiao Zhao, Guoquing Zhang, Kunwar Shailubhai, Stephen Comiskey, Rong Feng
  • Patent number: 10421787
    Abstract: The invention provides processes of preparing a peptide including a GCC agonist sequence selected from the group consisting of SEQ ID NOs: 1-249 described herein.
    Type: Grant
    Filed: January 13, 2017
    Date of Patent: September 24, 2019
    Assignee: Bausch Health Ireland Limited
    Inventors: Juncai Bai, Ruoping Zhang, Jun Jian, Junfeng Zhou, Qiao Zhao, Guoquing Zhang, Kunwar Shailubhai, Stephen Comiskey, Rong Feng
  • Publication number: 20190002501
    Abstract: The invention provides processes of purifying a peptide including a GCC agonist sequence selected from the group consisting of SEQ ID NOs: 1-251 described herein. The processes include a solvent exchange step before a freeze-drying (lyophilization) step.
    Type: Application
    Filed: June 5, 2018
    Publication date: January 3, 2019
    Inventors: Kunwar Shailubhai, Stephen Comiskey, Rong Feng, Juncai Bai, Ruoping Zhang, Jun Jia, Junfeng Zhou, Qiao Zhao, Guoqing Zhang
  • Patent number: 10011637
    Abstract: The invention provides processes of purifying a peptide including a GCC agonist sequence selected from the group consisting of SEQ ID NOs: 1-251 described herein. The processes include a solvent exchange step before a freeze-drying (lyophilization) step.
    Type: Grant
    Filed: June 5, 2014
    Date of Patent: July 3, 2018
    Assignee: SYNERGY PHARMACEUTICALS, INC.
    Inventors: Kunwar Shailubhai, Stephen Comiskey, Rong Feng, Juncai Bai, Ruoping Zhang, Jun Jia, Junfeng Zhou, Qiao Zhao, Guoqing Zhang
  • Publication number: 20170129925
    Abstract: The invention provides processes of preparing a peptide including a GCC agonist sequence selected from the group consisting of SEQ ID NOs: 1-249 described herein.
    Type: Application
    Filed: January 13, 2017
    Publication date: May 11, 2017
    Applicant: Synergy Pharmaceuticals Inc.
    Inventors: Juncai Bai, Ruoping Zhang, Jun Jian, Junfeng Zhou, Qiao Zhao, Guoquing Zhang, Kunwar Shailubhai, Stephen Comiskey, Rong Feng
  • Patent number: 9580471
    Abstract: The invention provides processes of preparing a peptide including a GCC agonist sequence selected from the group consisting of SEQ ID NOs: 1-249 described herein.
    Type: Grant
    Filed: March 1, 2012
    Date of Patent: February 28, 2017
    Assignee: SYNERGY PHARMACEUTICALS, INC.
    Inventors: Juncai Bai, Ruoping Zhang, Jun Jia, Junfeng Zhou, Qiao Zhao, Guoquing Zhang, Kunwar Shailubhai, Stephen Comiskey, Rong Feng
  • Publication number: 20170029467
    Abstract: The present disclosure provides a method of producing bivalirudin using a peptide fragment or peptide fragments on solid phase peptide synthesis that minimizes, or eliminates, the production of bivalirudin molecules having too few or too many glycine residues.
    Type: Application
    Filed: May 31, 2016
    Publication date: February 2, 2017
    Inventors: Guoqing Zhang, Ruoping Zhang, Juncai Bai
  • Publication number: 20160145307
    Abstract: The invention provides processes of purifying a peptide including a GCC agonist sequence selected from the group consisting of SEQ ID NOs: 1-251 described herein. The processes include a solvent exchange step before a freeze-drying (lyophilization) step.
    Type: Application
    Filed: June 5, 2014
    Publication date: May 26, 2016
    Inventors: Kunwar SHAILUBHAI, Stephen COMISKEY, Rong FENG, Juncai BAI, Ruoping ZHANG, Jun JIA, Junfeng ZHOU, Qiao ZHAO, Guoqing ZHANG
  • Publication number: 20140155575
    Abstract: The invention provides processes of preparing a peptide including a GCC agonist sequence selected from the group consisting of SEQ ID NOs: 1-249 described herein.
    Type: Application
    Filed: March 1, 2012
    Publication date: June 5, 2014
    Applicant: SYNERGY PHARMACEUTICALS INC.
    Inventors: Juncai Bai, Ruoping Zhang, Jun Jian, Junfeng Zhou, Qiao Zhao, Guoquing Zhang, Kunwar Shailubhai, Stephen Comiskey, Rong Feng
  • Publication number: 20130289241
    Abstract: A method for preparing exenatide by solid-phase synthesis, including: 1) mixing an Fmoc-Rink amide AM resin with a deprotecting agent to obtain a Rink amide AM resin; 2) condensing an Fmoc-Ser(tBu)-OH with the Rink amide AM resin to obtain an Fmoc-Ser(tBu)-Rink amide AM resin; 3) repeating the Fmoc deprotection and the condensation between an amino acid and a polypeptide on the resin, and condensing an amino acid with a polypeptide on the resin from the C-terminal to the N-terminal, to form a polypeptide resin; and 4) separating the polypeptide and the resin on the polypeptide resin.
    Type: Application
    Filed: April 26, 2012
    Publication date: October 31, 2013
    Applicant: SHANGHAI AMBIOPHARM, INC.
    Inventors: Juncai BAI, Guoqing ZHANG, Ruoping ZHANG
  • Publication number: 20110319594
    Abstract: A method for producing bivalirudin using solid phase peptide synthesis by: a) condensing Fmoc-Asn(Trt)-Gly-OH with a peptide resin of Asp(OtBu)11-Phe12-Glu(OtBu)13-Glu(OtBu)14-Ile15-Pro16-Glu(OtBu)17-Glu(OtBu)18-Tyr(tBu)19-Leu20-Resin; b) removing Fmoc-; c) condensing Fmoc-Gly-Gly-Gly-Gly-OH with the peptide resin; d) separately condensing Pro, Arg, Pro, and Phe with the peptide resin from C-terminal to N-terminal to yield a peptide resin of Boc-D-Phe1-Pro2-Arg(Pbf)3-Pro4-Gly5-Gly6-Gly7-Gly8-Asn(Trt)9-Gly10-Asp(OtBu)11-Phe12-Glu(OtBu)13-Glu(OtBu)14-Ile15-Pro16-Glu(OtBu)17-Glu(OtBu)18-Tyr(tBu)19-Leu20-Resin; and e) in the presence of a cleavage agent, separating a peptide from the peptide resin to yield bivalirudin represented by Formula VI. The method is low in cost and the resultant bivalirudin has high purity.
    Type: Application
    Filed: June 12, 2011
    Publication date: December 29, 2011
    Applicant: SHANGHAI AMBIOPHARM, INC.
    Inventors: Juncai BAI, Ruoping ZHANG, Yadong LIU, Guoqing ZHANG
  • Publication number: 20100292436
    Abstract: A method for producing bivalirudin using solid phase peptide synthesis by the following steps: a) mixing a Fmoc-amino acid resin or a Fmoc-peptide resin with a de-protective agent so as to remove Fmoc-; b) in the presence of a condensing agent, condensing a Fmoc- or Boc-amino acid with the amino acid or the peptide bound to the resin; c) repeating the steps a) and b) to yield a peptide resin represented by Formula I, (SEQ?ID?NO.?1) Boc-D-Phe1-Pro2-Arg(Pbf)3-Pro4-Gly5-Gly6-Gly7- Gly8-Asn(Trt)9-Gly10-Asp(OtBu)11-Phe12-Glu (OtBu)13-Glu(OtBu)14-Ile15-Pro16-Glu(OtBu)17-Glu (OtBu)18-Tyr(tBu)19-Leu20-Resin?(I) and d) in the presence of a cleavage agent, separating the peptide from the resin to yield bivalirudin represented by Formula II (SEQ ID NO. 2). D-Phe-Pro-Arg-Pro-Gly-Gly-Gly-Gly-Asn-Gly-Asp-Phe- Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu?(II) Based on its total volume, the de-protective agent is composed of between 3 and 20% of piperidine and between 0.
    Type: Application
    Filed: May 17, 2010
    Publication date: November 18, 2010
    Applicant: SHANGHAI AMBIOPHARM, INC.
    Inventors: Juncai BAI, Ruoping ZHANG, Yadong LIU, Guoqing ZHANG